Ornidale 500 Injection contains Ornidazole 500mg, a nitroimidazole antimicrobial agent widely used for the treatment of protozoal and anaerobic bacterial infections. It acts by disrupting DNA synthesis in susceptible organisms, leading to cell death and rapid clinical improvement.
Clinically, it is indicated for amoebiasis, giardiasis, trichomoniasis, bacterial vaginosis, and anaerobic infections of the gastrointestinal tract, liver, and soft tissues. Its efficacy against both protozoa and anaerobic bacteria makes it a versatile choice in hospital and outpatient settings.
The injection formulation ensures rapid systemic delivery, accurate dosing, and high bioavailability, which is particularly important in severe infections or when oral administration is not feasible. Ornidale 500 Injection is suitable for emergency care, hospital wards, and specialized infectious disease management.
Regular administration under medical supervision helps in resolving infections quickly, preventing complications, and supporting recovery. Ornidale 500 Injection remains a trusted therapy for effective management of protozoal and anaerobic bacterial infections, ensuring consistent patient outcomes.